BUPIVACAINE HYDROCHLORIDE INJECTION USP .25% SOLUTION

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

BUPIVACAINE HYDROCHLORIDE

Commercializzato da:

HOSPIRA HEALTHCARE ULC

Codice ATC:

N01BB01

INN (Nome Internazionale):

BUPIVACAINE

Dosaggio:

2.5MG

Forma farmaceutica:

SOLUTION

Composizione:

BUPIVACAINE HYDROCHLORIDE 2.5MG

Via di somministrazione:

BLOCK/INFILTRATION

Confezione:

10/20ML

Tipo di ricetta:

Ethical

Area terapeutica:

LOCAL ANESTHETICS

Dettagli prodotto:

Active ingredient group (AIG) number: 0108896001; AHFS:

Stato dell'autorizzazione:

CANCELLED POST MARKET

Data dell'autorizzazione:

2011-08-05

Scheda tecnica

PRODUCT MONOGRAPH
Pr
BUPIVACAINE HYDROCHLORIDE INJECTION, USP
(Bupivacaine Hydrochloride)
2.5 mg/mL, 5 mg/mL and 7.5 mg/mL
_Local Anesthetic_
Hospira Healthcare Corporation
DATE OF PREPARATION:
5400 Cote-de-Liesse
March 12, 2004
Town of Mount Royal (QC), CANADA
H4P 1A5
Control # 090308
- 2 -
PRODUCT MONOGRAPH
NAME OF DRUG
Pr
BUPIVACAINE HYDROCHLORIDE INJECTION, USP
(Bupivacaine Hydrochloride)
2.5 mg/mL, 5 mg/mL and 7.5 mg/mL
THERAPEUTIC CLASSIFICATION
Local Anesthetic
ACTION AND CLINICAL PHARMACOLOGY
Bupivacaine stabilizes the neuronal membrane and prevents both the
generation and the
conduction of nerve impulses, thereby exerting a local anesthetic
action.
The onset of action is rapid, and anesthesia is long lasting. The
advantage of bupivacaine over
other local anesthetics is in the prolonged duration of effective
anesthesia. It is to be noted
however, that the duration of action of a local anesthetic is
dependent on a number of factors
including site of injection, route of administration, concentration
and volume. It has also been
noted that there is a period of analgesia that persists after the
return of sensation, during which
time the need for strong analgesics is reduced.
Systemic absorption of local anesthetics produces effects on the
cardiovascular and central
nervous systems. At blood concentrations achieved with therapeutic
doses, changes in cardiac
conduction, excitability, refractoriness, contractility, and
peripheral vascular resistance are
minimal. However, toxic blood concentrations depress cardiac
conduction and excitability,
which may lead to atrioventricular block, ventricular arrhythmias and
to cardiac arrest. In
addition, myocardial contractility is depressed and peripheral
vasodilation occurs, leading to
decreased cardiac output and arterial blood pressure. Recent clinical
reports and animal
research suggest that these cardiovascular changes are more likely to
occur with bupivacaine
than other local anesthetics.
- 3 -
Following
systemic
absorption,
local
anesthetics
can
produce
central
nervo